Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 23990527)

1.

Varenicline may reduce negative effect while aiding smoking cessation.

Hays JT.

Evid Based Med. 2014 Feb;19(1):23. doi: 10.1136/eb-2013-101435. Epub 2013 Aug 29. No abstract available.

PMID:
23990527
2.

Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.

Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, Brown VL, Engelmann JM, Wetter DW.

JAMA Psychiatry. 2013 May;70(5):522-33. doi: 10.1001/jamapsychiatry.2013.678.

3.

Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".

Simon JA.

Arch Intern Med. 2011 Apr 25;171(8):777-8. doi: 10.1001/archinternmed.2011.137. No abstract available.

PMID:
21518947
4.

Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting.

Issa JS, Abe TO, Moura S, Santos PC, Pereira AC.

Nicotine Tob Res. 2013 Jun;15(6):1146-50. doi: 10.1093/ntr/nts230. Epub 2012 Nov 5.

PMID:
23128516
5.

Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.

Bailey SR, Crew EE, Riske EC, Ammerman S, Robinson TN, Killen JD.

Paediatr Drugs. 2012 Apr 1;14(2):91-108. doi: 10.2165/11594370-000000000-00000. Review.

6.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD006103. doi: 10.1002/14651858.CD006103.pub6. Review.

PMID:
22513936
7.

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.

Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.

Curr Med Res Opin. 2010 Mar;26(3):549-60. doi: 10.1185/03007990903542666.

PMID:
20050814
8.

[Medical therapy for smoking cessation].

Zeller A.

Ther Umsch. 2010 Aug;67(8):419-25. doi: 10.1024/0040-5930/a000074. German.

PMID:
20687045
9.

Changes in health-related quality of life with smoking cessation treatment.

Hays JT, Croghan IT, Baker CL, Cappelleri JC, Bushmakin AG.

Eur J Public Health. 2012 Apr;22(2):224-9. doi: 10.1093/eurpub/ckq137. Epub 2010 Sep 30.

10.

Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications?

Kotz D, Fidler JA, West R.

Nicotine Tob Res. 2011 Sep;13(9):793-9. doi: 10.1093/ntr/ntr075. Epub 2011 May 4.

PMID:
21543548
11.

Adherence to varenicline in the COMPASS smoking cessation intervention trial.

Catz SL, Jack LM, McClure JB, Javitz HS, Deprey M, Zbikowski SM, McAfee T, Richards J, Swan GE.

Nicotine Tob Res. 2011 May;13(5):361-8. doi: 10.1093/ntr/ntr003. Epub 2011 Feb 24.

12.

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.

Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR.

Thorax. 2008 Aug;63(8):717-24. doi: 10.1136/thx.2007.090647. Epub 2008 Feb 8.

13.

[Current and future medical drugs for smoking cessation].

Kusma B, Mache S, Deissenrieder F, Quarcoo D, Welte T, Groneberg D.

Laryngorhinootologie. 2009 Jun;88(6):410-9; quiz 420-2. doi: 10.1055/s-0029-1220929. Epub 2009 Jun 5. German.

PMID:
19504411
14.

Smoking cessation: an overview of treatment options with a focus on varenicline.

Stack NM.

Pharmacotherapy. 2007 Nov;27(11):1550-7. Review.

PMID:
17963463
15.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
16.

Improving the success of treating tobacco smokers.

Rigotti NA.

JAMA Intern Med. 2015 Feb;175(2):272-3. doi: 10.1001/jamainternmed.2014.6921. No abstract available.

PMID:
25545347
17.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
18.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
19.

The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.

Knight C, Howard P, Baker CL, Marton JP.

Value Health. 2010 Mar-Apr;13(2):209-14. doi: 10.1111/j.1524-4733.2009.00672.x. Epub 2009 Nov 13.

PMID:
19912599
20.

Smoking cessation-recent advances.

McNeil JJ, Piccenna L, Ioannides-Demos LL.

Cardiovasc Drugs Ther. 2010 Aug;24(4):359-67. doi: 10.1007/s10557-010-6246-8. Review.

PMID:
20602163
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk